Table 2. Details of chemotherapeutic treatment protocols; Author names of studies with significant survival benefit of HIPEC are underlined.
| Author | Year | Trial | Inclusion Criteria | Number of patients | IP cytotoxic drug | Dosage (mg/m2) | Volume (liters) | Systemic cytotoxic drug | Dosage | Cycle length (weeks) | Scheme |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ishigami | 2010 | Phase II | Cyto pos/PM | 40 | PTX | 20 | 1 | S-1 oral | 80 mg/m2/day | 3 | IP Day 1 & 8 |
| PTX i.v. | 50 mg/m2 | IV Day 1 & 8 | |||||||||
| S-1 Day 1–14 | |||||||||||
| Day 15–21 rest | |||||||||||
| Fujiwara | 2012 | Phase II | Cyto pos/PM | 18 | DOC | 40–60 | 1 | S-1 oral | 80 mg/m2/day | 3 | IP Day 1 |
| S-1 Day 1–14 | |||||||||||
| Day 15–21 rest | |||||||||||
| Imano | 2012 | Phase II | PM | 15 | PTX | 80 | 1 | S-1 oral | 80 mg/m2/day | 3 | IP Day 1 & 8 |
| PTX i.v. | 50 mg/m2 | IV Day 1 & 8 | |||||||||
| S-1 Day 1–14 | |||||||||||
| Day 15–21 rest | |||||||||||
| Fushida | 2013 | Phase II | PM | 27 | DOC | 35–50 | 1 | S-1 oral | 80 mg/m2/day | 4 | IP Day 1 & 15 |
| S-1 Day 1–14 | |||||||||||
| Day 15–28 rest | |||||||||||
| Yamaguchi | 2013 | Phase II | PM | 35 | PTX | 20 | 1 | S-1 oral | 80 mg/m2/day | 3 | IP Day 1 & 8 |
| PTX i.v. | 50 mg/m2 | IV Day 1 & 8 | |||||||||
| S-1 Day 1–14 | |||||||||||
| Day 15–21 rest | |||||||||||
| Ishigami | 2017 | Phase II | Cyto pos/PM | 100 | PTX | 20 | 1 | S-1 oral | 80 mg/m2/day | 3 | IP Day 1 & 8 |
| PTX i.v. | 50 mg/m2 | IV Day 1 & 8 | |||||||||
| S-1 Day 1–14 | |||||||||||
| Day 15–21 rest | |||||||||||
| Ishigami | 2018 | Phase III | PM | 164 | PTX | 20 | 0.5 | S-1 oral | 80 mg/m2/day | 3 | IP Day 1 & 8 |
| PTX i.v. | 50 mg/m2 | IV Day 1 & 8 | |||||||||
| S-1 Day 1–14 | |||||||||||
| Day 15–21 rest | |||||||||||
| Yonemura | 2020 | NRCT | Ctyo pos/PM | 419 | DOC | 30 | 0.5 | S-1 oral | 60 mg/m2/day | 3 | IP Day 1 |
| CIS | 30 | DOC i.v. | 30 mg/m2 | IV Day 8 | |||||||
| CIS i.v. | 30 mg/m2 | S-1 Day 1–14 | |||||||||
| Day 15–21 rest |
IP, intraperitoneally; NRCT, non-randomized controlled trial; Cyto pos, positive cytology; PM, peritoneal metastasis; i.v., intravenously; S1, tegafur/gimeracil/oteracil; PTX, paclitaxel; DOC, docetaxel; CIS, cisplatin.